Conflict of interest
In most American and some UK journals it is now customary for authors to be required to state whether or not there is a conflict of interest between what they have written and any sponsorship, actual or implied, that may be perceived to have been obtained from any agency involved in any product or policy that they are discussing or reporting upon. I wondered, when 'conflict of interest' policies were first developed, whether we should adopt similar mechanisms for 'Seizure'. Initially I thought this unnecessary since much conflict of interest is transparent (reports of drug trials, for instance, which, anyway, are independently refereed) and, since the number of opinion leaders in the epilepsy world is small, they would be known to the Editor who could prevent obvious abuses.
Recently, however, I have changed my mind, partly because I have seen how the policy works, partly because of a letter in our correspondence column, but also because of several recent experiences. In describing these experiences I am not going to name the agencies involved.
A short while ago I was asked, as were several UK opinion leaders, to take part in a series of (paid) presentations about a new drug whose uses and properties, for a variety of reasons, are little known in the UK. My presentation would be based on my assessment of the relevant literature (which included taking part in a very instructive Advisory Board in the United States) and on my early experience of the drug (but not on personal trial experience). It was to be, as far as I could determine, an exposition of what, having weighed up the evidence, my clinical practice with the drug would be (indeed I used as the basis for it the instruction leaflet on the drug I had already prepared for my junior medical and nursing staff on the use and indications for the new drug in our clinic). Initial discussion about the meeting was with a medical communication company (who behaved entirely properly throughout) and was merely concerned with preparing an abstract and developing the necessary slide material. I was looking forward to the actual meeting since, as is now common in such meetings, there were to be other participants (speaking not about the drug itself but on other aspects of epilepsy) and I had invited two speakers whom I had particularly wanted to hear.
However, shortly before the meeting I received a fax of my abstract, scribbled over with comments which I can only conclude had come from someone in the company itself inviting me to shade my opinion, not say some of the things I was going to say and emphasize points that I think would have made the piece factually wrong. I could only refuse, resign my chairmanship of the meeting and not give my presentation, which, I understand, was given by someone else. This was an easy decision to make, and I am sure was the right one. But it led me to wonder, uneasily, about two things. Had my colleague, who had taken over, said the things that I had been asked to say and felt I could not: had my colleagues who gave their presentation in various parts of the country also, unwittingly, been compromised into giving the company view?
This lead me to contemplate the number of satellite symposia at many conferences I have attended (most with a remarkably similar Faculty) usually with a bright catchy name and an optimistic review of the particular company's new drug. It would be difficult to judge how biased such presentations would be, but a conflict of interest statement by each speaker might be illuminating, although, since such presentations are usually held in exotic locations, the combined effects of jet lag, travellers diarrhoea and exuberant hospitality has usually blunted the audience's critical faculties.
Recently 'Seizure' received a manuscript relating to a head to head trial comparing two newer drugs: there was no placebo arm to the trial. Statistically, as the paper admitted, the trial was under powered. And yet the paper very heavily promoted one of the drugs over the other (although both seemed equally effective within the limited significance testing that an under powered trial can provide). Perusal of the manuscript revealed that the study had probably been funded by the particular company whose drug appeared to be advantageous. No conflict of interest was stated.
With two colleagues I have recently been reviewing the literature relating to the putative relationship between epilepsy, its treatment and the polycystic ovary syndrome. The literature is muddled and confused and open to different interpretations, particularly because the epilepsy world, spurred on by commercial interests, has blundered into an area that was already controversial (since the concept of the polycystic ovary syndrome is changing from a structural one to a hormonal/metabolic one) and the syndrome has legitimately different definitions in the USA and the UK. Thus it is possible to make apparently contradictory statements about its prevalence in epilepsy and its association with the use of a particular drug without necessarily being wrong, but still being potentially misleading. So, in reading any review of the subject, at the moment, in the epilepsy literature, one has to ask 'who sponsored this?' Our own review will appear in 'Seizure' shortly, hopefully unbiased, but will contain a statement of possible conflict of interest.
And, as Editor, I am going to have to ask you to do the same. Our instructions to authors will be modified to ask our authors, routinely, to state any potential conflict of interest between any possible commercial or governmental sponsorship and the piece in question. Conflict of interest might arise if the author had been paid to write the piece, if he or she was giving their name to a piece 'ghosted' by someone else, if the piece of research had been sponsored by a government or a company, or if the authors' department or research programme was dependant on sponsorship or donation from a relevant company or the writer had shares in the company (unlikely in the UK). If you do not make a declaration, we may ask you to do so. And, although it is probably impossible to totally eradicate ghost writing-much as journals dislike it-if you are part, say, of a focus group or research team whose deliberations or research is being written up by a third party: do read it very carefully before you put your name to it and ensure it accurately reflects your views and ask 'Is there a possible conflict of interest here?'
Tim Betts Editor

CONFLICT OF INTEREST
Journals worldwide are dependent on advertizing revenue and so, potentially, are not completely free from conflict of interest. The main conflict of interest in this editorial is that I may have offended several parties: but I think it had to be written. Blatant commercial pressure is not good for us, our readers, the health services using public whom we serve nor, least of all, for the commercial company itself.
